Home About Fees Articles Contact
Book or enquire
Services

GLP-1 Exit Strategy

Deprescribing

Independent Medication Review

Clinical Data Review

Metabolic Health

Lifestyle Medicine

Understand

High Blood Pressure

Women's HRT

Men's Hormones

After a Heart Attack

Pre-Diabetes

Normal Bloods, Feel Terrible

After Hospital

GLP-1 Exit Strategy · Mounjaro · Wegovy · Ozempic

Coming off Mounjaro, Wegovy or Ozempic: what to expect and what to do next.

For most people, appetite returns within weeks of stopping. Weight regain often follows within months.

That is not a willpower problem. It is a planning problem. This consultation exists to fix it.

Book your Exit Strategy Review — £495

This is a clinical review and planning consultation. It is not a prescription shortcut, not a guarantee of a particular outcome, and not a recommendation to stop medication. Sometimes continuing treatment is the right clinical decision.

Clinical appointments via CQC-registered Sutton Medical Consulting

NICE recommends that people stopping weight-loss medication should be offered support to prevent regain and weight cycling. In practice, many patients prescribed privately leave treatment without a structured exit plan. This is what that support looks like when it is done properly.

Initial Consultation
£495
60-minute review
  • History and results reviewed in advance
  • Decision on tapering, stopping, or maintenance
  • Monitoring strategy for appetite and weight
  • Practical maintenance framework
  • Clear written plan to take away
  • GP communication where appropriate
Book your Exit Strategy Review

Follow-up support from £125

Available in-person or by video consultation

See the GLP-1 withdrawal timeline tool →

You are in the right place if any of these are true.

The people who book this review are not looking for motivation. They already know what good looks like. What they do not have is a medically serious plan for what happens when the medication stops doing the work.

Most private GLP-1 clinics are set up to start treatment. Very few are set up to plan what comes after it. This one is.

  • You are on Mounjaro, Wegovy or Ozempic and want to stop — but you have no plan for what happens to appetite and weight when you do
  • You have already stopped and hunger has returned faster than you expected
  • You lost significant weight but you do not trust it will hold without the medication
  • You were prescribed treatment privately and given little or no guidance on long-term maintenance
  • You want a clinically defensible answer — not generic lifestyle advice and not guesswork
  • You want to understand whether continuing, reducing, or stopping is actually the right next step for you

The medication was never the whole story.

GLP-1 drugs work by suppressing appetite, slowing gastric emptying, and reducing food noise. For most people, they work well. The problem is that none of those mechanisms persist after the medication stops.

When semaglutide was stopped in the STEP 4 trial, participants regained on average two thirds of their lost weight within 12 months. When tirzepatide was stopped in SURMOUNT-4, the pattern was similar.

This is not a failure of the medication. It is what happens when a pharmacological support is removed without anything in place to replace what it was doing. Appetite returns. Food noise returns. The old patterns return.

The question is not whether this will happen. The question is what is in place to manage it when it does.

"The question is not merely whether the medication worked. The question is what needs to be in place if the result is going to hold."

— Dr Dan Reardon · NHS A&E Doctor · GMC 6098984
of lost weight regained within 12 months of stopping semaglutide without a maintenance plan
~50%
of weight regained within 12 months after stopping tirzepatide

You leave with a clear written plan.

Not more information. A medically defensible plan for what happens next — specific to you, not a generic protocol.

The decision

Whether to taper, stop, continue, or move into a maintenance phase — with the clinical reasoning behind it.

Monitoring strategy

What to track for appetite, weight, waist, symptoms, and relevant markers — and at what intervals.

Maintenance framework

A practical structure for food, movement, and recovery that works on normal weeks, not just perfect ones.

Early warning markers

Clear signals that the plan is working — and clear signals that it is beginning to drift — before it becomes a problem.

Contingency plan

What to do if hunger, weight, or old patterns begin to return — so you have a response before you need one.

GP communication

A clear written summary to your GP where appropriate, keeping your care coordinated and documented.

"You have already invested in treatment. This is what protects that investment when the medication stops."

Book your Exit Strategy Review

The Exit Plan.
Structured support through the transition.

Most people who have spent 6–18 months on GLP-1 medication — typically £200–400 per month — have made a significant financial and personal investment in getting results. A single consultation gives you the plan. The Exit Plan gives you the support to execute it.

It is not a coaching programme. It is a structured clinical follow-up — designed to catch problems early, adjust the plan when needed, and give you a clinical contact point through the period when rebound risk is highest.

  • One 60-minute initial Exit Strategy Review
  • One 30-minute follow-up review at 4–6 weeks
  • One 15-minute results and adjustment review
  • Written plan updated at each stage
  • GP communication where appropriate
  • Clinical contact point through the highest-risk period
Structured Package
The Exit Plan
£695
Initial review + 2 follow-ups · 6–12 weeks

For patients who want structured clinical support through the transition and maintenance period — not just a plan, but a clinician alongside them while it matters most.

Book The Exit Plan

Saves £70 vs individual appointments · Most popular choice

A doctor-led service. Not a medication funnel.

Most GLP-1 clinics are commercially tied to keeping patients on treatment. This service is not. The goal is the most clinically defensible next step for you — which may be continuation, reduction, or stopping.

Dr Dan Reardon is an NHS A&E doctor working in frontline emergency medicine alongside his private practice. That combination — clinical judgment under pressure, metabolic medicine, and a decade building evidence-based health systems — is what makes the plans different.

Not ideological. Not anti-medication. Clinically serious.

Also treating: SSRIs, PPIs, statins, and blood pressure medication · View all fees

NHS A&E DoctorFrontline emergency medicine · active
MB ChB · BSc · MScCardiff & Birmingham
GMC 6098984Fully registered
Deprescribing SpecialistGLP-1, SSRIs, PPIs, statins, antihypertensives
Former FitnessGenes CEOA decade in metabolic health and evidence-based physiology
CQC-Registered PracticeVia Sutton Medical Consulting, Sutton Coldfield

GLP-1 Exit Strategy

Fees reflect more than appointment length. They include advance review of your history and results, clinical interpretation, and a clear written plan.

Initial Exit Strategy Review
£495
60 minutes

Full review, written plan, decision on next phase. The right starting point for most patients.

Follow-up Review
£195
30 minutes

Progress review, results, plan refinement, and next-step decisions.

Results & Adjustment
£125
15 minutes

Smaller adjustments or review of agreed data points.

The Exit Plan (initial review + 2 follow-ups) is available as a structured package for £695. See above. · View all consultation fees →

Consultations available in-person at Sutton Coldfield or by video.

Investigation costs are separate. Where further testing is indicated, the review will identify exactly which tests are needed and the most appropriate route — NHS, GP referral, or private lab.

×

Not a prescription shortcut. A medical review, not a route to medication without clinical assessment.

×

Not a weight-loss programme. No targets, weigh-ins, or coaching calls.

×

Not motivational coaching. Clinical judgment, not lifestyle cheerleading.

×

Not anti-medication. Sometimes continuation is the right answer. The review arrives at the most defensible next step.

FAQ

How quickly does appetite return after stopping Mounjaro or Wegovy?
For most people, appetite begins to return within one to two weeks of stopping. Food noise — the persistent background preoccupation with eating — often returns before hunger itself becomes physically intense. The speed and severity vary depending on how long you were on treatment, the dose you were on, and what metabolic and behavioural infrastructure is already in place. This is exactly why the transition period needs a plan, not guesswork. See also: what to expect when stopping semaglutide and what to expect when stopping tirzepatide.
Will I regain all the weight I lost?
Not necessarily — but the risk is real and well-evidenced. The STEP 4 trial found that people who stopped semaglutide regained on average two thirds of their lost weight within 12 months without a maintenance plan. SURMOUNT-4 showed a similar pattern with tirzepatide. What you had in place before stopping — strength, routine, appetite management, sleep, and a clear plan — makes a significant difference to whether regain is partial, gradual, or rapid. That is what this review is designed to build.
Is tapering better than stopping suddenly?
For most people, yes. A gradual step-down gives the body and appetite more time to adjust, and it gives you time to build the behavioural and metabolic infrastructure that the medication was partly doing for you. Abrupt stopping tends to produce a sharper return of appetite and a faster rebound pattern. Whether tapering is the right approach for you specifically depends on your current dose, how long you have been on treatment, and your overall clinical picture — which is what the consultation reviews.
Should I stay on a low maintenance dose instead of stopping completely?
For some people, a maintenance dose is clinically appropriate and worth considering seriously. It is not a failure — it is a medical decision. The review will look at whether maintenance dosing makes sense for your situation, what the risk-benefit looks like, and whether there are alternatives to indefinite continuation. Sometimes the right answer is continuation. Sometimes it is a structured exit. The goal is the most defensible clinical decision for you, not a predetermined outcome.
Do I always need to stop treatment?
No. Sometimes continuation is the right decision. The review exists to make that call properly — not to push people off medication.
What if my medication was prescribed by an online clinic?
That is not a problem. Many people have had a straightforward route into treatment through online prescribers and a much thinner route out of it. The source of the original prescription does not change what is needed now. The review works with wherever you are and whatever you have been prescribed.
How is this different from going back to my prescribing clinic?
Most prescribing clinics are set up to start treatment, not to plan what comes after it. The commercial incentive is typically to keep patients on treatment. This review is specifically focused on the transition — tapering, stopping, or building a maintenance structure — not prescription renewal. The goal is the right clinical answer, not a predetermined commercial one.
How long should follow-up support last?
The highest-risk period for rebound is typically the first three to six months after stopping. That is when appetite has returned, the pharmacological support is gone, and the maintenance infrastructure is being tested for the first time. A single consultation gives you a plan for that period. The Exit Plan package provides structured clinical check-ins through it — a 30-minute review at four to six weeks and a 15-minute adjustment review — so there is a clinical contact point when problems are most likely to emerge.

If you want the evidence.

Deprescribing
Coming Off Wegovy and Ozempic: What to Expect
The evidence-backed guide to stopping semaglutide — appetite, weight, and how to plan the off-ramp properly. →
Deprescribing
Coming Off Mounjaro: What to Expect When Stopping Tirzepatide
A week-by-week guide to stopping Mounjaro — what happens when tirzepatide clears your system. →
Evidence Briefing
What Happens When Semaglutide Is Stopped? What STEP 4 Showed
The trial behind the ⅔ regain figure — what it showed and what it means clinically. →
Evidence Briefing
What Happens When Tirzepatide Is Stopped? What SURMOUNT-4 Showed
What happened when tirzepatide was withdrawn after 36 weeks — and why maintenance planning matters. →
Clinical Evidence
Why GLP-1 Drugs Work Better for Some People Than Others
What genetics, dose, drug choice, and duration actually explain about variable response. →
Evidence Briefing
SURMOUNT-5: Tirzepatide vs Semaglutide Head-to-Head
What the head-to-head obesity trial showed and what it means in practice. →
View all articles →

You have already done the hard part. Don't lose it without a plan.

Book your GLP-1 Exit Strategy Review and leave with a written plan for what happens next.

Book your Exit Strategy Review — £395

Clinical appointments via CQC-registered Sutton Medical Consulting · Sutton Coldfield · Video available